TITLE

Can a Pill Save You from Yourself?

AUTHOR(S)
Hirshberg, Charles
PUB. DATE
April 2006
SOURCE
Men's Health;Apr2006, Vol. 21 Issue 3, p140
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article provides information on the drug Acomplia. The drug could well be just the first of a whole new class of drugs that work by taking advantage of one of the most intriguing biological discoveries of the past 20 years, the endocannabinoid system. To study these sorts of effects, Sanofi-Aventis tested its potential blockbuster on a huge scale, recruiting more than 13,000 people in both Europe and North America to sample the medicine's effectiveness in smoking cessation, weight loss, and the prevention of type-2 diabetes.
ACCESSION #
20284565

 

Related Articles

  • The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482 

    Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement...

  • Sanofi's dengue vaccine rounds final corner. Mullard, Asher // Nature Reviews Drug Discovery;Nov2014, Vol. 13 Issue 11, p801 

    The article reports on the completion of the Phase III clinical trials for the CYD-TDV dengue virus vaccine developed by pharmaceutical company Sanofi-Aventis SA. The clinical trials highlight the effectiveness of the vaccine in preventing and treating mosquito-borne diseases. Also discussed are...

  • Obesity Drug In the Wings.  // Nutrition Business Journal;Mar2005, Vol. 10 Issue 3, p10 

    Reports on French company Sanofi-Aventis' preparation for the launch of a weight loss drug called rimonabant, brand name Acomplia, in 2006. Drug's targeting of the endocannabinoid system in the brain, believed to play a role in regulating appetite; Estimated sales of the drug in the U.S. if it...

  • Iniparib Misses in Breast Cancer; Sanofi Still in Genzyme Talks.  // Bioworld Week;2/7/2011, Vol. 19 Issue 6, p2 

    The article offers information related to Sanofi-Aventis SA such as the failure of its poly ADP-ribose polymerase (PARP) inhibitor BSI-201 or iniparib to hit its endpoint in a Phase III trial for metastatic triple-negative breast cancer and the extension of the company's tender offer to acquire...

  • Sanofi announces results of ORIGIN.  // BioSpectrum;Jul2012, Vol. 10 Issue 7, p115 

    The article reports on the announcement of Sanofi-Aventis SA on the results of the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial that assesses the effects of treatment with insulin glargine versus standard care on cardiovascular (CV) outcomes.

  • Asthma treatment passes trial. Investor's Business Daily // Investors Business Daily;11/12/2014, pA02 

    The article announces the positive results of the phase two of the study for dupilumab in patients with moderate to severe uncontrolled asthma, jointly conducted by pharmaceutical firms Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA.

  • Merrimack Pharmaceuticals' Series G Brings in $77M. Shaffer, Catherine // BioWorld Today;4/18/2011, Vol. 22 Issue 74, p1 

    The article offers information on a Series G financing completed by Merrimack Pharmaceuticals Inc. The company raised 77 million U.S. dollars, which will be used to fund the development of five clinical-stage cancer candidates, three pre-clinical candidates and various research-stage programs....

  • WEIGHT LOSS MEDICATION INCREASES DEPRESSION RISK.  // RN;Dec2007, Vol. 70 Issue 12, p30 

    The article focuses on a meta-analyis of rimonabant which revealed that the weight-loss drug increases the risk of depression and anxiety and can increase users' suicidal thoughts. The drug targets the endocannabinoid system of the brain, which helps trigger and reward food intake....

  • Disappointment at rimonabant halt.  // Independent Nurse;11/3/2008, p4 

    The article reports on clinicians' disappointment on the suspension of the weight-loss drug rimonabant, issued by the European Medicines Agency (EMEA). It is stated that EMEA raised concerns about the risk of psychiatric disorders in patients treated with the drug, and warned no further...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics